Tscan Therapeutics Inc (TCRX)
US$ 1.59-0.63%
Price Chart
Key Statistics
Market Cap
$ 90.54M
P/E Ratio
0.00
Revenue (TTM)
$ 2.82M
Volume
304.09K
52W High
$ 9.69
52W Low
$ 1.02
Dividend Yield
0.00%
Beta
1.08
Technicals
50-Day MA
1.6033
200-Day MA
3.8445
52 Week High
9.69
52 Week Low
1.02
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Employees
194
Headquarters
Waltham, MA
CEO
Dr. Gavin MacBeath Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg